Petros Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Petros Pharmaceuticals Inc's ROI in the second quarter of 2026?
Petros Pharmaceuticals Inc recorded a cumulative net loss of $-3 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -125.72%.

Within the Healthcare sector 656 other companies had a higher return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. 37.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	37.92 %	-41.62 %	-92.14 %	-98.28 %	-94.17 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	1	2	3	3	4
Return On Investment (TTM)	-125.72 %	124.23 %	233.39 %	-3487.58 %	-1020.86 %
PTPI's Overall Ranking	# 37	# 37	# 392	# 3214	# 2722
Seq. Investment Change TTM	-30.07 %	207.6 %	160.8 %	-75.41 %	-70.4 %
Seq. Net Income Change TTM	-	63.72 %	-	-	-
Net Income (TTM) in Millions	-3	4	2	-14	-16

PTPI Company Profile >> Back to PTPI Roi Comparisons >> See Annual PTPI Return On Investment

Return On Investment PTPI's Ranking
Within:	No.
Industry	# 293
Sector	# 657
Overall	# 37

Return On Investment Statistics
High	Average	Low
233.39 %	-275.61 %	-3487.58 %
(Dec 31 2025)		(Sep 30 2025)

Financial Statements
Petros Pharmaceuticals Inc's II. Quarter Investments	$ 1 Millions	PTPI's Balance sheet
Petros Pharmaceuticals Inc's II. Quarter Income	$ -1 Millions	Quarterly PTPI's Income Statement
PTPI's Income by Division		See PTPI's Income by Division

PTPI Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2020) 2021
Total Investments in Millions	3	0	39	26	25
Y / Y Investment Growth	667.83 %	-99.05 %	51.86 %	2.17 %	-
Net Income in Millions	3	-14	-8	-20	-21
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	100.58 %	-3829.58 %	-20.75 %	-77.34 %	-81.17 %

Annual Roi Comment

In the fiscal year 2025 ROI improved to 100.58 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PTPI's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PTPI's Competitors
Subscribers only: Roi for Petros Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for PTPI's Customers

Other Ratios
PTPI's Roa	PTPI's Inventory Turnover Ratio	PTPI's Growth Rates	PTPI's Dividend Statistics
	PTPI's Profitability Ratios	PTPI's Asset Turnover Ratio	PTPI's Dividend Growth
PTPI's Roe	PTPI's Valuation Ratios	PTPI's Financial Strength Ratios	PTPI's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-03T12:09:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.